Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial [0.03%]
乌特伊多隆联合卡培他滨治疗复发性三阴性乳腺癌的疗效：一项随机III期对照试验的最终分析
B Xu,T Sun,Q Zhang et al.
B Xu et al.
Background: Primary analysis of the phase III trial BG01-1323L demonstrated that utidelone plus capecitabine significantly improved progression-free survival (PFS) and overall response rate (ORR) versus capecitabine alone...
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma [0.03%]
预测胰腺导管腺癌辅助吉西他滨敏感性的转录特征研究
R Nicolle,O Gayet,P Duconseil et al.
R Nicolle et al.
Background: Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of ...
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial [0.03%]
III期随机试验：taselisib或安慰剂联合氟维司群治疗ER阳性、PIK3CA突变、HER2阴性晚期乳腺癌患者的疗效：SANDPIPER研究
S Dent,J Cortés,Y-H Im et al.
S Dent et al.
Background: The phase III SANDPIPER study assessed taselisib (GDC-0032), a potent, selective PI3K inhibitor, plus fulvestrant in estrogen receptor-positive, HER2-negative, PIK3CA-mutant locally advanced or metastatic brea...
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations [0.03%]
非门控激酶RET突变介导的塞尔帕替尼和普拉西替获得性耐药性的结构基础
V Subbiah,T Shen,S S Terzyan et al.
V Subbiah et al.
Background: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung cancer (NS...
Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial [0.03%]
用于治疗晚期非小细胞肺癌的纳米聚合物微胶粒紫杉醇与溶剂型紫杉醇一线疗法比较：一项开放标签、随机、多中心III期临床试验
M Shi,A Gu,H Tu et al.
M Shi et al.
Background: Polymeric micellar paclitaxel (pm-Pac) is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel. We aimed to compare the efficacy and safety between pm-Pac plus cisplatin and solvent-based...
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers [0.03%]
一种新型的CCT3833联合抑制剂可有效作用于突变型KRAS驱动的癌症
G Saturno,F Lopes,I Niculescu-Duvaz et al.
G Saturno et al.
Background: KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but thera...
How often do highly promising cancer biology discoveries translate into effective treatments? [0.03%]
极具前景的癌症生物学发现究竟有多少能够转化为有效的治疗方法？
R S Waters,V Prasad
R S Waters
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial [0.03%]
奥沙利铂辅助化疗持续时间（3个月与6个月）在高危II期结肠癌患者中的疗效：III期随机试验(Achieve-2研究)
K Yamazaki,T Yamanaka,M Shiozawa et al.
K Yamazaki et al.
Background: Oxaliplatin-based adjuvant chemotherapy may be associated with debilitating peripheral sensory neuropathy (PSN) in patients with high-risk stage II colon cancer. This open-label, multicenter, randomized phase ...